CHANGES TO THE PORTFOLIO
Gland Pharma was a recent addition to the portfolio, providing a one-of-a-kind chance to play the CRAMS market thanks to its diverse array of licensed drugs.In the injectable manufacturing industry, there are just a few businesses that offer CDMO services. It has a good cash conversion rate and can consider non-organic growth options. Other development potential on the horizon include biologics, China entrance, and row market expansion, giving it a clear multi-year growth story with difficult-to-replicate capabilities.